Abstract:
:Microphthalmia transcription factor (Mitf) is involved in melanocyte development and differentiation. We previously reported that Mitf expression, as detected by immunohistochemical analysis, is an independent prognostic marker in patients with intermediate-thickness melanoma. However, the clinical significance of Mitf expression in melanoma is not well delineated. In this prospective study, we attempted to demonstrate the correlation between Mitf expression in primary melanoma and the sentinel lymph node status and prognosis. We prospectively examined primary cutaneous melanomas from 94 patients undergoing nodal staging by sentinel lymph node biopsy. We quantified the percentage of tumor cells whose nuclei stained with the Mitf antibody visually. Survival curves were generated using the Kaplan-Meier method. The correlation between Mitf expression and nodal status was evaluated using the Mann-Whitney U-test. Here we demonstrate that Mitf expression is directly correlated with both disease-free survival (DFS) and overall survival (OS) over a median follow-up of 28.5 months. The mean DFS and OS in the eight patients whose melanomas did not stain positive for Mitf were 15.75±3.36 months (median, 12 months) and 38.17±5.18 months (median, 29 months), respectively. These results are significantly lower than those for patients who showed evidence of Mitf expression, in whom the mean DFS and OS were 66.1±4.03 months (median, not reached, P=0.0001) and 66.75±38.17 months (median, not reached, P=0.0001), respectively. The mean DFS and OS with greater than 25% (67 patients) of the melanoma cells staining positive for Mitf expression were 78.37±2.78 and 82.38±1.6 months, respectively, compared with 26.37±3.2 months (P=0.0001) and 44.53±4.5 months (P=0.0001), respectively, with up to 25% (27 patients) of cells stained positive for Mitf expression. In addition, there was a significant relationship between Mitf expression and nodal status, as evaluated by sentinel node biopsy. For example, none of the melanomas with greater than 50% Mitf expression had a positive sentinel node biopsy. Our study shows that expression of the molecular marker Mitf in primary cutaneous melanomas is a useful tool in assessing lymph node status. Mitf immunostaining in the primary tumor serves as a reliable predictor of occult lymph node metastases, as well as a favorable prognosticator of DFS and OS in melanoma patients.
journal_name
Melanoma Resjournal_title
Melanoma researchauthors
Naffouje S,Naffouje R,Bhagwandin S,Salti GIdoi
10.1097/CMR.0000000000000195subject
Has Abstractpub_date
2015-12-01 00:00:00pages
496-502issue
6eissn
0960-8931issn
1473-5636journal_volume
25pub_type
杂志文章abstract::Tumor cell invasion through basement membranes and into stromal tissue are key steps for promoting growth and metastasis. Tumor cells express various extracellular-matrix-degrading enzymes such as matrix metalloproteinases (MMPs) to degrade extracellular matrix components to facilitate tumor migration and invasion. Hi...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0b013e3282a660ad
更新日期:2007-08-01 00:00:00
abstract::Tyrosinase is the key enzyme in melanin biosynthesis in pigmented cells. We transfected 9L rat glioma cells with human tyrosinase cDNA that had been cloned in a high expression vector. Stable transfectants were selected by their resistance to the antibiotic G418. More than a dozen G418-resistant clones were isolated a...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-199812000-00003
更新日期:1998-12-01 00:00:00
abstract::In a previous qualitative study it has been shown that the incorporation of pre-existing collagen bundles from the reticular dermis into the bulk of melanoma lesions metastatic to the skin indicates rapid systemic spread. In the present study the amount of pre-existing dermal collagen in the bulk of the melanoma lesio...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-199804000-00010
更新日期:1998-04-01 00:00:00
abstract::Amelanotic melanomas (AMMs) account for a small proportion of all melanomas. They pose a risk of delayed diagnosis and, consequently, poor prognosis. AMMs may atypically present as a pyogenic granuloma-like lesion. This study sought to investigate the prevalence and clinical and histological features of AMM masqueradi...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0000000000000451
更新日期:2018-08-01 00:00:00
abstract::Downstream of Ras, the serine/threonine kinase B-raf has been reported to be mutated, amongst other carcinomas, in a substantial subset of primary melanomas, with a preponderance of mutations within the kinase domain, including the activating V599E and V599K transitions. We investigated a representative series of 54 r...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-200510000-00011
更新日期:2005-10-01 00:00:00
abstract::In this study we evaluated the overexpression status of HER-2 and its prognostic significance on survival in patients with thick cutaneous malignant melanoma. The immuno-alkaline phosphatase antigen detection technique was applied to archival diagnostic material from 51 patients with primary lesions measuring >or= 10 ...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-200204000-00006
更新日期:2002-04-01 00:00:00
abstract::The growth rate (GR) of melanomas is not uniform. A fast-growing subtype has been identified and seems to have a role in the stabilization of the mortality rates because of melanoma. To examine features associated with fast-growing melanomas (FGMs) and to determine the relationship between the GR and well-recognized p...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0b013e328342f312
更新日期:2011-04-01 00:00:00
abstract::Melanomas are promising targets for immunotherapy, as they express a number of tissue-specific antigens against which immune responses can be elicited. We have previously described transgenic mice in which malignant cutaneous melanomas are produced. The 1042 melanoma cell line, derived from a primary melanoma in one o...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-200412000-00019
更新日期:2004-12-01 00:00:00
abstract::The Eastern Cooperative Oncology Group consensus guidelines from 2016 recommend interruption of targeted therapy with BRAF- and MEK-inhibitors during radiotherapy with data being based mostly on BRAF monotherapy. The aim of this study is to provide data on the safety of concurrent radiotherapy and combination targeted...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0000000000000682
更新日期:2020-12-01 00:00:00
abstract::We studied the efficacy, tolerability and clinical courses of dabrafenib in patients with metastatic melanoma who were ineligible for enrolment into a clinical trial. Between July 2011 and May 2013, patients with unresectable stage III or stage IV, V600-mutated metastatic melanoma who were not eligible for inclusion i...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0000000000000036
更新日期:2014-04-01 00:00:00
abstract::The treatment of cancer during pregnancy presents a unique challenge. Optimal treatments are often altered or even delayed to protect fetal growth and organogenesis. The landscape of cancer treatment has shifted dramatically over the past several years and treatment with checkpoint inhibitors, including anti-PD1 and a...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0000000000000657
更新日期:2020-08-01 00:00:00
abstract::Pigmented basal cell carcinoma (PBCC) is a tumour with distinct clinical features which occasionally may be difficult to differentiate from malignant melanoma (MM). The purpose of this study was to re-examine the epiluminescence microscopy (ELM) criteria for PBCC and to determine their statistical significance in the ...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-199708000-00005
更新日期:1997-08-01 00:00:00
abstract::The objective of this study was to identify novel tumor-suppressor genes in melanoma, using an integrative genomic approach. Data from: (i) earlier reports of DNA loss and gain in malignant melanoma accompanied by comparative genomic hybridization high-definition array data of the entire human genome; (ii) microarray ...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0b013e328344a003
更新日期:2011-08-01 00:00:00
abstract::Both in vitro and in vivo observations have suggested that melatonin modulates malignant cell growth. The present studies aimed to characterize the interactions of melatonin with cultured murine B16 melanoma cells. Time- and temperature-dependent specific melatonin accumulation by B16 murine melanoma cells was observe...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-199311000-00003
更新日期:1993-12-01 00:00:00
abstract::Ipilimumab is approved for adjuvant melanoma treatment at a dose of 10 mg/kg, but its use is limited owing to high toxicity and treatment-associated costs. We retrospectively analyzed 29 patients who underwent complete resection of stage IIC-III melanoma and were treated with ipilimumab 3 mg/kg in an adjuvant setting....
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0000000000000593
更新日期:2019-12-01 00:00:00
abstract::Many melanoma epitopes are presented to cytotoxic T-lymphocytes (CTLs) by major histocompatibility complex (MHC) class I molecules, and it is reasonable to expect that the epitopes would be good substrates for the transporter associated with antigen processing (TAP), as TAP plays a major role in the transport of pepti...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-199808000-00008
更新日期:1998-08-01 00:00:00
abstract::Prognostic groups defined by lactate dehydrogenase concentration and number of organ sites containing metastases have been reported for patients treated with dabrafenib and trametinib for advanced melanoma. We aimed to validate these prognostic groups for patients treated with vemurafenib and cobimetinib in the coBRIM...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0000000000000634
更新日期:2020-06-01 00:00:00
abstract::As the cost of air travel has decreased substantially in the USA and Europe over the past few decades, leisure travel to vacation destinations during the winter months has expanded significantly. This trend has probably increased the incidence of significant ultraviolet radiation exposure and sunburn in a broader popu...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/01.cmr.0000195696.50390.23
更新日期:2006-02-01 00:00:00
abstract::This study addressed the impact of exposure to ultraviolet radiation on the risk of cutaneous malignant melanoma (CMM), as well as the behavioral components at stake in its occurrence. We performed a one-to-one unmatched case-control study among subjects aged 20 years or more with naturally non-pigmented skin in Germa...
journal_title:Melanoma research
pub_type: 杂志文章,多中心研究
doi:10.1097/00008390-199404000-00001
更新日期:1994-04-01 00:00:00
abstract::Putative tumour suppressor genes CDKN2A and CDKN2B (on chromosome 9p21) and CDKN2A-interacting cell growth regulatory genes CDK4 and Id-1 have been demonstrated to be involved in the pathogenesis of malignant melanoma (MM). Mutation analysis of these candidate genes was performed in MM families from southern Italy wit...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-200312000-00006
更新日期:2003-12-01 00:00:00
abstract::Melanomas contain subsets of cancer stem-like cells with tumor-initiating capacity. The frequency of these cells in the tumor is still a topic of debate. We investigated the phenotypic plasticity of cancer cells grown as melanospheres to elucidate the influence of the microenvironment on some features of melanoma stem...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0b013e3283531317
更新日期:2012-06-01 00:00:00
abstract::BRAF mutations are found in ~50% of metastatic melanomas, most commonly in codon V600. Vemurafenib improves progression-free survival and overall survival in patients with advanced BRAF-mutated melanoma. The results of a descriptive study evaluating vemurafenib in patients with advanced melanoma harbouring BRAF mutati...
journal_title:Melanoma research
pub_type: 杂志文章,多中心研究
doi:10.1097/CMR.0000000000000398
更新日期:2017-12-01 00:00:00
abstract::CD8 T-cell infiltration of metastatic melanoma may be a useful biomarker for prediction of prognosis and response to therapy. The heterogeneous distribution of CD8 T cells within a single tumor, and across different tumors within a single patient, may complicate quantification of infiltration. However, the impact of h...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0000000000000330
更新日期:2017-06-01 00:00:00
abstract::The aim of this study was to evaluate metastatic latency and survival after the occurrence of metastases in patients with choroidal/ciliary body melanoma treated with proton therapy. This was a retrospective cohort study. All consecutive patients with choroidal/ciliary body melanoma treated with proton therapy between...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0000000000000519
更新日期:2020-06-01 00:00:00
abstract::Cell free extracts from metastases of human melanoma contain a highly active ribonucleoside diphosphate reductase (RR) which uses guanosine diphosphate (GDP) as substrate and deoxythymidine triphosphate (dTTP) as effector. No activity could be detected in these extracts when cytidine diphosphate (CDP) was used as the ...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-199212000-00014
更新日期:1992-12-01 00:00:00
abstract::Melanoma is the deadliest form of skin cancer. Ipilimumab, a novel immunotherapy, is the first treatment shown to improve survival in patients with metastatic melanoma in large randomized controlled studies. The most concerning side effects reported in clinical studies of ipilimumab fall into the category of immune-re...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0b013e32835c7e68
更新日期:2013-02-01 00:00:00
abstract::When cancer cells, including melanoma cells, are genetically altered to secrete cytokines, irradiated and injected into subjects, long-term antitumour immunity is induced. Optimally, existing melanomas induced to produce cytokines in vivo could stimulate this same immune response. Although in vivo electroporation enha...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-200012000-00010
更新日期:2000-12-01 00:00:00
abstract::Cerebral metastases from melanoma are correlated with a poor prognosis. Temozolomide is an oral alkylating agent that can cross the blood-brain barrier and in phase II and III trials, patients with advanced metastatic melanoma achieved overall response rates of 13 to 21%. The present study evaluated the efficacy and t...
journal_title:Melanoma research
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/01.cmr.0000136707.60108.ab
更新日期:2004-08-01 00:00:00
abstract::Concurrent BRAF-MEK inhibition improves clinical outcomes in patients with advanced BRAF V600E/K-mutant melanoma. There is currently less evidence for the efficacy of this treatment in patients with rare BRAF non-V600E/K genotypes. We report on two patients with rare BRAF exon 15 mutations - BRAF A598_T599insV and V60...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0000000000000376
更新日期:2017-10-01 00:00:00
abstract::Ipilimumab (anti-CTLA-4 antibody) is a new tool for the treatment of metastatic melanoma patients that has led to an improvement in survival rates worldwide. New types of toxicities have been described with ipilimumab called 'immune-related adverse events' or irAEs. Here, we report an acute and steroid resistant case ...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0b013e32835fb524
更新日期:2013-06-01 00:00:00